Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury

Nature Nanotechnology

Volumn 9, Issue 12, 2014, Pages 1054-1062

  Gaudin, Alice ^a,b   Yemisci, Müge ^c   Eroglu, Hakan ^c   Lepetre Mouelhi, Sinda ^a,b   Turkoglu, Omer Faruk ^d   Dönmez Demir, Buket ^c   Caban, Seçil ^c   Sargon, Mustafa Fevzi ^c   Garcia Argote, Sébastien ^e   Pieters, Grégory ^e   Loreau, Olivier ^e   Rousseau, Bernard ^e   Tagit, Oya ^f   Hildebrandt, Niko ^f   Le Dantec, Yannick ^g   Mougin, Julie ^a,b   Valetti, Sabrina ^a,b   Chacun, Hélène ^a,b   Nicolas, Valérie ^f   Desmaële, Didier ^a,b   Andrieux, Karine ^a,b   Capan, Yilmaz ^c   Dalkara, Turgay ^c   Couvreur, Patrick ^a,b   more..

^a UNIV PARIS SUD   (France)

^b Labex d'Excellence NanoSaclay   (France)

^c HACETTEPE UNIVERSITY   (Turkey)

^d ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g University of Paris XI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY;

CEREBRAL ISCHAEMIA; METABOLIZATION; MOTOR RECOVERY; NANO-ASSEMBLIES; NEUROPROTECTION; RAT SPINAL CORD; SPINAL CORD INJURIES (SCI); SYSTEMIC ADMINISTRATION;

PATIENT REHABILITATION;

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE DERIVATIVE; NANOPARTICLE; SQUALENE DERIVATIVE; SQUALENOYL ADENOSINE NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; BRAIN ISCHEMIA; BRAIN MICROCIRCULATION; CEREBROVASCULAR ACCIDENT; CIRCULATION; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG CONJUGATION; ERYTHROCYTE COUNT; FOOD INTAKE; FORELIMB; HINDLIMB; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; MALE; MICROVASCULATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE FIBER; NEUROPROTECTION; NONHUMAN; NONREM SLEEP; PRIORITY JOURNAL; RAT; REM SLEEP; REPERFUSION; SPINAL CORD INJURY; SURFACE CHARGE; SYSTEMIC CIRCULATION; TRANSMISSION ELECTRON MICROSCOPY; WEIGHT VARIATION; WHITE MATTER;

EID: 84926155314     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2014.274     Document Type: Article

References (44)

1. Profyris, C. et al. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol. Dis. 15, 415-436 (2004).
2. Pardridge, W. M. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm. Sci. Technol. Today 2, 49-59 (1999).
3. Palmer, A. M. & Alavijeh, M. S. Translational CNS medicines research. Drug. Discov. Today 17, 1068-1078 (2012).
4. Pangalos, M. N., Schechter, L. E. & Hurko, O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nature Rev. Drug Discov. 6, 521-532 (2007).
5. Zhang, L., Zhang, Z. G. & Chopp, M. The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol. Sci. 33, 415-422 (2012).
6. Andrieux, K. & Couvreur, P. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1, 463-474 (2009).
7. Nair, S. B., Dileep, A. & Rajanikant, G. K. Nanotechnology based diagnostic and therapeutic strategies for neuroscience with special emphasis on ischemic stroke. Curr. Med. Chem. 19, 744-756 (2012).
8. Sun, Q., Radosz, M. & Shen, Y. Challenges in design of translational nanocarriers. J. Control Rel. 164, 156-169 (2012).
9. Yang, H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res. 27, 1759-1771 (2010).
10. Boison, D. Adenosine as a neuromodulator in neurological diseases. Curr. Opin. Pharmacol. 8, 2-7 (2008).
11. De Mendonca, A., Sebastiao, A. M. & Ribeiro, J. A. Adenosine: does it have a neuroprotective role after all Brain Res. Rev. 33, 258-274 (2000).
12. Williams-Karnesky, R. L. & Stenzel-Poore, M. P. Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant. Curr. Neuropharmacol. 7, 217-227 (2009).
13. Fredholm, B. B., Chen, J. F., Cunha, R. A., Svenningsson, P. & Vaugeois, J. M. Adenosine and brain function. Int. Rev. Neurobiol. 63, 191-270 (2005).
14. Gomes, C. V., Kaster, M. P., Tome, A. R., Agostinho, P. M. & Cunha, R. A. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim. Biophys. Acta 1808, 1380-1399 (2011).
15. Moser, G. H., Schrader, J. & Deussen, A. Turnover of adenosine in plasma of human and dog blood. Am. J. Physiol. 256, C799-C806 (1989).
16. Cerqueira, M. D., Verani, M. S., Schwaiger, M., Heo, J. & Iskandrian, A. S. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J. Am. Coll. Cardiol. 23, 384-389 (1994).
17. Levine, A. S. & Morley, J. E. Purinergic regulation of food intake. Science 217, 77-79 (1982).
18. Basheer, R., Strecker, R. E., Thakkar, M. M. & McCarley, R. W. Adenosine and sleep-wake regulation. Prog. Neurobiol. 73, 379-396 (2004).
19. Pardridge, W. M., Yoshikawa, T., Kang, Y. S. & Miller, L. P. Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. J. Pharmacol. Exp. Ther. 268, 14-18 (1994).
20. Isakovic, A. J., Abbott, N. J. & Redzic, Z. B. Brain to blood efflux transport of adenosine: blood-brain barrier studies in the rat. J. Neurochem. 90, 272-286 (2004).
21. Couvreur, P. et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 6, 2544-2548 (2006).
22. Reddy, L. H. et al. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J. Pharmacol. Exp. Ther. 325, 484-490 (2008).
23. Hillaireau, H. et al. Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies. Biomaterials 34, 4831-4838 (2013).
24. Bisgaier, C. L., Minton, L. L., Essenburg, A. D., White, A. & Homan, R. Use of fluorescent cholesteryl ester microemulsions in cholesteryl ester transfer protein assays. J. Lipid Res. 34, 1625-1634 (1993).
25. Kitagawa, H., Mori, A., Shimada, J., Mitsumoto, Y. & Kikuchi, T. Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats. Neurol. Res. 24, 317-323 (2002).
26. Tatlisumak, T. et al. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke 29, 1952-1958 (1998).
27. Pignataro, G., Simon, R. P. & Boison, D. Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. J. Cereb. Blood Flow Metab. 27, 1-5 (2007).
28. Von Lubitz, D. K. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept Eur. J. Pharmacol. 371, 85-102 (1999).
29. Echavarria-Pinto, M. et al. Low coronary microcirculatory resistance associated with profound hypotension during intravenous adenosine infusion: implications for the functional assessment of coronary stenoses. Circ. Cardiovasc. Interv. 7, 35-42 (2014).
30. Go, A. S. et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129, e28-e292 (2014).
31. Yemisci, M. et al. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nature Med. 15, 1031-1037 (2009).
32. Hamilton, N. B., Attwell, D. & Hall, C. N. Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front. Neuroenerg. 2, 1-14 (2010).
33. Li, S. et al. Intracellular ATP concentration contributes to the cytotoxic and cytoprotective effects of adenosine. PLoS ONE 8, e76731 (2013).
34. Paterniti, I. et al. Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects. J. Neuroinflam. 8, 31 (2011).
35. Okonkwo, D. O. et al. A comparison of adenosine A2A agonism and methylprednisolone in attenuating neuronal damage and improving functional outcome after experimental traumatic spinal cord injury in rabbits. J. Neurosurg. Spine 4, 64-70 (2006).
36. Kwon, B. K., Hillyer, J. & Tetzlaff, W. Translational research in spinal cord injury: a survey of opinion from the SCI community. J. Neurotrauma 27, 21-33 (2010).
37. Basso, D. M., Beattie, M. S. & Bresnahan, J. C. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp. Neurol. 139, 244-256 (1996).
38. Shi, Y. et al. Effective repair of traumatically injured spinal cord by nanoscale block copolymer micelles. Nature Nanotech. 5, 80-87 (2010).
39. Alavijeh, M. S. & Palmer, A. M. Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds. Neurobiol. Dis. 37, 38-47 (2010).
40. Levine, A. S. & Morley, J. E. Effect of intraventricular adenosine on food intake in rats. Pharmacol. Biochem. Behav. 19, 23-26 (1983).
41. Portas, C. M., Thakkar, M., Rainnie, D. G., Greene, R. W. & McCarley, R. W. Role of adenosine in behavioral state modulation: a microdialysis study in the freely moving cat. Neuroscience 79, 225-235 (1997).
42. Porkka-Heiskanen, T., Alanko, L., Kalinchuk, A. & Stenberg, D. Adenosine and sleep. Sleep Med. Rev. 6, 321-332 (2002).
43. Melani, A., Corti, F., Cellai, L., Giuliana Vannucchi, M. & Pedata, F. Low doses of the selective adenosine A2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia. Brain Res. 1551, 59-72 (2014).
44. Poller, B. et al. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J. Neurochem. 107, 1358-1368 (2008).